Recombinant Human Thyrotropin for Management of Metastatic Differentiated Thyroid Carcinoma in Patients With Deficient Reserve of Endogenous Thyrotropin

A Basu; HS Abu-Lebdeh; D Erickson; RS Bahn; ID Hay; V Fatourechi

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Recombinant Human Thyrotropin for Management of Metastatic Differentiated Thyroid Carcinoma in Patients With Deficient Reserve of Endogenous Thyrotropin

Author(s):

A Basu¹,

HS Abu-Lebdeh¹,

D Erickson¹,

RS Bahn¹,

ID Hay¹,

V Fatourechi^2,*

1Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, USA

2Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, lovejoy.Margery@mayo.edu, USA

International Journal of Endocrinology and Metabolism:Vol. 3, issue 3; 130-135

Article type:Research Article

Received:Apr 08, 2005

Accepted:Aug 10, 2005

How to Cite:A BasuHS Abu-LebdehD EricksonRS BahnID HayV Fatourechiet al.Recombinant Human Thyrotropin for Management of Metastatic Differentiated Thyroid Carcinoma in Patients With Deficient Reserve of Endogenous Thyrotropin.Int J Endocrinol Metab.3(3):130-135.

Abstract

adioiodine (RAI) therapy for metastatic follicular cell–derived thyroid cancer (FCDC) requires elevated levels of serum TSH, usually achieved by withdrawal of thyroxine therapy. This is not possible in FCDC associated with hypopituitarism, because of the absence of endogenous TSH. However, the advent of recombinant human TSH (rhTSH) has made diagnostic 131I whole body scans and subsequent RAI therapy possible for patients with FCDC who have deficiency of endogenous TSH. Recently, several reports have been published of patients with metastatic FCDC and pituitary tumor treated after rhTSH administration. We describe 2 cases of FCDC with hypopituitarism, in which therapeutic RAI intervention was possible only with rhTSH administration. Materials and Methods: We searched our medical records from 1950 through 1999 to determine the prevalence of FCDC metastases to the pituitary. Results: We identified 19 cases of FCDC with concomitant hypopituitarism but only 1 with metastasis of FCDC to the sellar region. Of the 19 patients, 2 were treated with rhTSH before RAI therapy. Conclusions: Although metastasis of FCDC to the pituitary is rare as shown by our study, association of pituitary insufficiency with FCDC is more common. The availability of rhTSH has improved therapy for these patients.

Keywords

Full Text

Full text is available in PDF

comments